Health Care Select Sect SPDR ETF (XLV) - NYSEARCA
  • Oct. 22, 2013, 1:25 PM
    • The mutual fund giant greatly boosts its ETF presence, rolling out 10 sector ETFs on Thursday, with BlackRock (BLK) - whose iShares has its own suite of sector ETFs - as the funds' sub-advisor. State Street (STT), though, is better-known for its sector offerings. Launching on Thursday - and popular existing State Street SPDR ETFs they'll be competing with:
    • Fidelity MSCI Consumer Staples Index ETF (FSTA) - XLP.
    • Fidelity MSCI Consumer Discretionary Index ETF (FDIS) - XLY.
    • Fidelity MSCI Energy Index ETF (FENY) - XLE.
    • Fidelity MSCI Financials Index ETF (FNCL) - XLF.
    • Fidelity MSCI Health Care Index ETF (FHLC) - XLV.
    • Fidelity MSCI Industrials Index ETF (FIDU) - XLI.
    • Fidelity MSCI Information Technology Index ETF (FTEC) - XLK.
    • Fidelity MSCI Materials Index ETF (FMAT) - XLB.
    • Fidelity MSCI Telecommunications Services Index ETF (FCOM) - XTL.
    • Fidelity MSCI Utilities Index ETF (FUTY) - XLU.
    | Oct. 22, 2013, 1:25 PM | 1 Comment
  • Oct. 20, 2013, 3:46 AM
    • Health-insurance exchanges have reportedly received 476,000 applications for coverage, White House officials have said, although they wouldn't say how many people have received coverage.
    • It's not certain whether the Obamacare program is on course to enroll 7M people within the six-month sign-up period, as projected by the Congressional Budget Office
    • The Web sites of the exchanges have been hit with numerous technical problems that have prevented people from buying coverage and caused health insurers to receive inaccurate information.
    • ETFs: XLV, XHE, VHT, FXH, IHF, IHI, IYH, PTH, RYH, PSCH, RXL, RXD, XHS.
    | Oct. 20, 2013, 3:46 AM | 3 Comments
  • Oct. 18, 2013, 4:36 AM
    • The technology problems afflicting the roll-out of health-insurance exchanges seem to be even worse than thought, with insurers saying that the marketplaces are generating incorrect information.
    • "Errors include duplicate enrollments, spouses reported as children, missing data fields and suspect eligibility determinations," the WSJ writes.
    • The problems are damaging the ability of insurers to process even the small numbers of people who have signed up. "The longer this takes to resolve...the harder it will be to get people to (come back and) sign up," said Aetna (AET) CEO Mark Bertolini.
    • Other firms that could be affected include UnitedHealth (UNH), WellPoint (WLP), Humana (HUM) and Molina Healthcare (MOH).
    • The IT contractors involved include IBM (IBM), Infosys (INFY) and CGI Group (GIB).
    • ETFs: XLV, XHE, VHT, FXH, IHF, IHI, IYH, PTH, RYH, PSCH, RXL, RXD, XHS.
    | Oct. 18, 2013, 4:36 AM | 11 Comments
  • Oct. 16, 2013, 3:21 PM
    • It's a good year for large-cap core mutual funds, with 46% beating the S&P 500 vs. a 10-year average of just 36%, according to Goldman Sachs.
    • The study finds most are overweight health care (XLV), which not coincidentally happens to be the best-performing sector this year, up 30%.
    • The funds are most underweight utilities (XLU), which just happen to be the second worst-performing sector YTD, up 10%. Only telecoms have done worse.
    • Chasing performance? May be, but the team finds the funds have tended to be present in the good performers for the last 12 months, and have retreated from discretionary stocks (XLY) of late despite their outperformance.
    • Individual names? CVS Caremark (CVS), JPMorgan (JPM), and Cisco (CSCO) are the stocks liked the most vs. the benchmark.
    • Health care ETFs: XLV, XHE, VHT, FXH, IHF, IHI, IYH, PTH, RYH, PSCH, RXL, RXD, XHS.
    • Utility ETFs: IDU, PUI, XLU, VPU, RYU, FXU, PSCU, UPW, SDP, UTLT.
    | Oct. 16, 2013, 3:21 PM
  • Oct. 13, 2013, 2:59 AM
    • California Governor Jerry Brown has vetoed a bill that would have limited the use of biosimilar pharmaceuticals in the state.
    • Brown explained that the legislation was premature, as the FDA hasn't yet set the rules governing such drugs.
    • Biosimilars are the copycat versions of biotech drugs - also known as biologics - which are complex proteins developed in living cells. Biosimilars are not called generics, as it's difficult to prove that they're exactly the same as the biologic original.
    • The campaign to limit the use of biosimilars has been led by Amgen (AMGN) and Genentech (RHHBY.OB); so far, 10 states have blocked such efforts this year, including Illinois and Texas.
    • Companies developing biosimilars include Hospira (HSP), Novartis (NVS), Momenta Pharmaceuticals (MNTA), Baxter (BAX) and Teva (TEVA).
    • Healthcare ETFs: XLV, XHE, VHT, FXH, IHF, IHI, IYH, PTH, RYH, PSCH, RXL, RXD, XHS
    | Oct. 13, 2013, 2:59 AM
  • Oct. 2, 2013, 4:07 AM
    • Millions of people visited the Web sites of health-insurance exchanges yesterday on their first day of operations, although, as expected, many of the sites were beset by technical glitches.
    • It's unclear how much of the traffic translated into sales - Connecticut's site received 28,000 hits as of 4 pm but only 167 people had applied to buy insurance.
    • The exchanges have been created as a key part of Obamacare.
    • Health insurers that are selling plans on exchanges include UnitedHealth (UNH), Aetna (AET), WellPoint (WLP), Health Net (HNT) and Humana (HUM). Molina Healthcare (MOH) is also playing a role.
    • ETFs: XLV, XHE, VHT, FXH, IHF, IHI, IYH, PTH, RYH, PSCH, RXL, RXD, XHS.
    | Oct. 2, 2013, 4:07 AM | 2 Comments
  • Sep. 29, 2013, 1:50 AM
    • While the health exchanges that are a key part of Obamacare are due to open for business on Tuesday, some states won't be able to offer full functionality at first because of IT problems.
    • The states include New York, Oregon and Colorado, as well as the District of Columbia.
    • In addition, the Obamacare Spanish-language Internet site won't be ready, while small businesses and their staff won't be able to sign up for weeks.
    • The contractors involved include IBM (IBM) and Infosys (INFY)
    • ETFs: XLV, XHE, VHT, FXH, IHF, IHI, IYH, PTH, RYH, PSCH, RXL, RXD, XHS.
    | Sep. 29, 2013, 1:50 AM | 17 Comments
  • Sep. 25, 2013, 3:08 AM
    • The average cost of a mid-tier health insurance plan under Obamacare is $328 a month, price data from the government showed yesterday, just a week before enrollment in the healthcare overhaul is due to begin on October 1.
    • As you'd expect, prices were cheaper in the states with more competition.
    • The Obama administration hopes to sign up 7M consumers in the first year, with 2.7M young and healthy Americans set to pay for those who are older and sicker. The average premium for a 27-year-old nonsmoker will range from $163-$240 a month.
    • Health insurers that intend to sell plans on some exchanges include UnitedHealth (UNH), Aetna (AET), WellPoint (WLP) and Humana (HUM). Molina Healthcare (MOH) is also set to play a role.
    • ETFs: XLV, XHE, VHT, FXH, IHF, IHI, IYH, PTH, RYH, PSCH, RXL, RXD, XHS.
    | Sep. 25, 2013, 3:08 AM | 8 Comments
  • Sep. 12, 2013, 10:07 AM
    • U.S. bio-pharmaceutical companies are developing 271 vaccines to prevent and even treat numerous conditions, a report from the Pharmaceutical Research & Manufacturers of America says.
    • The conditions targeted include infectious diseases and various forms of cancer and neurological disorders.
    • In the U.S., 10 infectious diseases have been at least 90% eradicated because of vaccines.
    • ETFs: XLV, XHE, VHT, FXH, IHF, IHI, IYH, PTH, RYH, PSCH, RXL, RXD, XHS, XPH, IHE, PJP, PPH, DRGS
    | Sep. 12, 2013, 10:07 AM
  • Aug. 17, 2013, 9:02 AM
    • The market's more richly valued than you think, writes Jack Hough in Barron's, as Q4 S&P 500 (SPY) earnings are expected to rise 10.5% on just a 0.6% increase in revenue. "Where's that margin growth going to come from," asks S&P's Howard Silverblatt. "Most of us aren't exactly napping on the job as it is."
    • Avoid sectors particularly prone to estimates cuts like consumer discretionary (XLY) and telecom (IYZ), suggests Hough, but favor safer groups like tech (XLK, though Cisco last week calls "safe" into question) and health care (XLV).
    • A stock screen scoring companies by free cash yield as well as ability to still boost margins yields 5 top picks:
    • Pfizer (PFE) trades inline with a slow-grower like Merck (MRK) but maybe deserves a multiple closer to a fast-grower like Bristol-Myers Squibb (BMY).
    • Danaher (DHR) - it trades at what seems like a pricey 18x earnings, but just 15x projected free cash.
    • Lear (LEA) at 10x earnings is growing faster than the auto market as a whole as it picks up market share and electrical content in cars is rising.
    • Oracle (ORCL) and Qualcomm (QCOM) have both seen earnings growing faster than their share price of late, leaving them attractively priced.
    • The screen also yielded 3 to avoid:
    • Tiffany (TIF) at 20x earnings is pricing in faster earnings growth in 2014. Praxair (PX) expectations are for a near-doubling in earnings growth to 13%. Lennar (LEN) with 32% projected earnings growth remains pricey even as the housing recovery appears to be slowing.
    | Aug. 17, 2013, 9:02 AM | 3 Comments
  • Jul. 4, 2013, 3:28 AM

    The FDA intends to allow generic pharmaceutical companies to alter the safety labels on their products if they become aware of new risks. The change could make the firms liable if they don't warn patients about the concerns about a product. Generic makers have been protected from such liability since 2011, when the Supreme Court said they couldn't be sued because they had to use the same labels as as their brand name counterparts. (PR)

    | Jul. 4, 2013, 3:28 AM
  • Jul. 3, 2013, 8:41 AM

    Some health insurers are suffering moderate losses premarket following the government's decision to delay a rule that requires companies with more than 50 workers to provide health coverage, although many appear to be untraded at the moment. Aetna (AET) -1.1%, UnitedHealth (UNH) -1.2% and Humana (HUM) -0.3%.

    | Jul. 3, 2013, 8:41 AM
  • Jul. 2, 2013, 11:07 AM

    GE's (GE -0.7%) healthcare unit released secondary research findings today, indicating that bad habits and lifestyle choices are contributing approximately $33.9M annually to costs related to cancer. Furthermore, the same research revealed that by reducing bad habits, global healthcare systems could potentially save $25B each year.

    | Jul. 2, 2013, 11:07 AM | 4 Comments
  • Jul. 2, 2013, 7:02 AM

    The market for biotech IPOs is experiencing its best run in nine years, with 16 companies raising $1.1B in H1. An increase in FDA drug approvals, a strong performance by some biotech firms that are already listed, and the JOBS Act, which allows companies to privately "test the waters" before publicly launching an IPO process, are some of the factors behind the trend. Companies to benefit include heart-drug company Esperion Therapeutics (ESPR), and Prosensa Holding (RNA), a developer of treatments for rare diseases.

    | Jul. 2, 2013, 7:02 AM
  • Jun. 26, 2013, 10:40 AM
    43 out of 45 global markets are oversold, according to BAML's "Breadth Buy" indicator. These extreme signals tend to be followed by a short-term 6-7% bounce, but, cautions chief investment strategist Michael Hartnett, a sustained rally would require a shift in policy behavior. What's more, the 2 markets not in oversold territory are the U.S. (SPY) and Japan (EWJ, DXJ) and they're kind of important. Most oversold: Brazil (EWZ), Turkey (TUR), South Africa (EZA), Mexico (EWW), Materials (XLB), China (FXI, CAF). Least oversold (in addition to the U.S. and Japan): Health Care (XLV, IYH), and Consumer Discretionary (XLY).
    | Jun. 26, 2013, 10:40 AM
  • Jun. 25, 2013, 3:19 AM

    In a major victory for the generic pharmaceuticals industry, the Supreme Court yesterday ruled that patients can't sue firms over copycat drugs that are allegedly unsafe. The court quashed a New Hampshire jury's decision to award $21M to a woman who developed a debilitating skin disease after she took a generic version of the pain treatment sulindac made by a unit of India's Sun Pharmaceutical.

    | Jun. 25, 2013, 3:19 AM | 5 Comments
XLV Description
The Health Care Select Sector SPDR® Fund, before expenses, seeks to closely match the returns and characteristics of the Health Care Select Sector Index. Our approach is designed to provide portfolios with low portfolio turnover, accurate tracking, and lower costs.
See more details on sponsor's website
Sector: Healthcare
Country: United States
ETF Hub
Find the right ETFs for your portfolio: Visit Seeking Alpha's ETF Hub